Scientists believe they have discovered a way to "steer" the immune system to kill cancers.
Researchers
at University College, London have developed a way of finding unique
markings within a tumour - its "Achilles heel" - allowing the body to
target the disease.
But the personalised method, reported in Science journal, would be expensive and has not yet been tried in patients.
Experts said the idea made sense but could be more complicated in reality.
However,
the researchers, whose work was funded by Cancer Research UK, believe
their discovery could form the backbone of new treatments and hope to
test it in patients within two years.
They believe by analysing the DNA, they'll be able to develop bespoke treatment.
People have tried to steer the immune system to kill tumours before, but cancer vaccines have largely flopped.
One explanation is that they are training the body's own defences to go after the wrong target.
The
problem is cancers are not made up of identical cells - they are a
heavily mutated, genetic mess and samples at different sites within a
tumour can look and behave very differently.
'Exciting'
They grow a bit like a tree with core "trunk" mutations, but then mutations that branch off in all directions. It is known as cancer heterogeneity.
The international study developed a way of discovering the "trunk"
mutations that change antigens - the proteins that stick out from the
surface of cancer cells.
Professor Charles Swanton, from the UCL
Cancer Institute, added: "This is exciting. Now we can prioritise and
target tumour antigens that are present in every cell - the Achilles
heel of these highly complex cancers.
"This is really fascinating
and takes personalised medicine to its absolute limit, where each
patient would have a unique, bespoke treatment."
There are two approaches being suggested for targeting the trunk mutations.
The first is to develop cancer vaccines for each patient that train the immune system to spot them.
The
second is to "fish" for immune cells that already target those
mutations and swell their numbers in the lab, and then put them back
into the body.
'Early days'
Dr
Marco Gerlinger, from the Institute of Cancer Research, said: "This is a
very important step and makes us think about heterogeneity as a problem
and why this gives cancer this big advantage.
"Targeting trunk mutations makes sense from many points of view, but
it is early days and whether it's that simple, I'm not entirely sure.
"Many
cancers are not standing still but they keep evolving constantly. These
are moving targets which makes it difficult to get them under control.
"Cancers that can change and evolve could lose the initial
antigen or maybe come up with smokescreens of other good antigens so
that the immune system gets confused."
Some immunotherapy treatments work spectacularly with some patients' cancer disappearing entirely.
They take the brakes off the immune system, freeing it up to fight cancer.
The
researchers hope the combination of removing the immune system's brakes
and then taking over the steering wheel, will save lives.
Professor
Peter Johnson, from Cancer Research UK, said the research had shown
"impressive results in the clinic" and although "the technology is
complicated and quite recent... once you start doing it the cost will
come down".
'Elegant study'
Dr
Stefan Symeonides, clinician scientist in experimental cancer medicine
at the University of Edinburgh, said designing a personalised vaccine
was currently impractical, especially when a patient needed treatment
straight away.
But he added that the "very elegant" study did
provide a ground-breaking insight into current immunotherapy drugs,
which do not yet work for most people.
"It's not just the number of antigens, it's how many of the cancer cells have them," he said.
"This
data will be quoted in discussions for years, as we try to understand
which patients benefit from immunotherapy drugs, which ones don't, and
why, so we can improve those therapies."
No comments:
Post a Comment